{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:13Z","timestamp":1791920833889,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiph.2024.102630","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:10:39Z","timestamp":1735258239000},"page":"102630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study"],"prefix":"10.1016","volume":"18","author":[{"given":"Rachawit","family":"Setpakdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-4704","authenticated-orcid":false,"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2024.102630_bib1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jacc.2012.02.024","article-title":"Sudden cardiac death in patients with human immunodeficiency virus infection","volume":"59","author":"Tseng","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jiph.2024.102630_bib2","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"9","author":"Kandel","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jiph.2024.102630_bib3","first-page":"e35","article-title":"Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet","volume":"2","author":"Croxford","year":"2017","journal-title":"Public Health"},{"key":"10.1016\/j.jiph.2024.102630_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4102\/sajhivmed.v19i1.817","article-title":"An overview of tenofovir and renal disease for the HIV-treating clinician","volume":"19","author":"Venter","year":"2018","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.jiph.2024.102630_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.antiviral.2010.10.006","article-title":"Metabolic and neurologic consequences of chronic lopinavir\/ritonavir administration to C57BL\/6 mice","volume":"88","author":"Pistell","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiph.2024.102630_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/17571472.2014.11493422","article-title":"The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough","volume":"6","author":"Lorenc","year":"2014","journal-title":"Lond J Prim Care (Abingdon)"},{"key":"10.1016\/j.jiph.2024.102630_bib7","series-title":"[sited 2024 Feb 12]","article-title":"Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach [Internet]","author":"Consolidated Guidelines on HIV Prevention","year":"2021"},{"key":"10.1016\/j.jiph.2024.102630_bib8","unstructured":"Thailand National guideline on HIV\/AIDS treatment and prevention 2021\/2022 [Internet]. 2021 [cited 2022 Sep 12]. Available from: https:\/\/www.thaiaidssociety.org23hailandd-hiv-aids-guideline\/."},{"key":"10.1016\/j.jiph.2024.102630_bib9","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2024.102630_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2024.102630_bib11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","article-title":"Implications of weight gain with newer antiretrovirals: 10-year predictions of cardiovascular disease and diabetes","volume":"35","author":"McCann","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jiph.2024.102630_bib12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/IDR.S203813","article-title":"Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir\/abacavir\/lamivudine: data from the SCOLTA project","volume":"12","author":"Bagella","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2024.102630_bib13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.35755\/jmedassocthai.2023.10.13897","article-title":"Outcomes of dolutegravir-based antiretroviral therapy in Thai youth aged 18 to 24 years living with HIV in Bangkok: a retrospective cohort study","volume":"106","author":"Songtaweesin","year":"2023","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.jiph.2024.102630_bib14","doi-asserted-by":"crossref","first-page":"2242250","DOI":"10.1080\/07853890.2023.2242250","article-title":"Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study","volume":"55","author":"Hirigo","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.jiph.2024.102630_bib15","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/cid\/ciaa1652","article-title":"Transition to dolutegravir is associated with an increase in the rate of body mass index change in a cohort of virally suppressed adolescents","volume":"73","author":"Neil","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2024.102630_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Effectiveness and tolerability of dolutegravir\/lamivudine for the treatment of HIV-1 infection in clinical practice","volume":"78","author":"In\u00e9s","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2024.102630_bib17","doi-asserted-by":"crossref","unstructured":"Anters S., Renaud F., Rangaraj A., Zhang K., Limbrick-Oldfield E., Hughes M., 2022. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. eClinicalMedicine 2022;48:101412.","DOI":"10.1016\/j.eclinm.2022.101412"},{"key":"10.1016\/j.jiph.2024.102630_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/QAI.0000000000002661","article-title":"Genetic associations with weight gain among South Africans who initiated dolutegravir-containing and tenofovir-containing regimens","volume":"87","author":"Cindi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiph.2024.102630_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess Weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiph.2024.102630_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","article-title":"Comparative changes of lipid levels in treatmentna\u00efvee, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks","volume":"35","author":"Quercia","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jiph.2024.102630_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.33393\/dti.2023.2529","article-title":"Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir","volume":"17","author":"Khemla","year":"2023","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.jiph.2024.102630_bib22","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.3390\/jcm12113644","article-title":"Weight and metabolic outcomes in na\u00efve HIV patients treated with integrase inhibitor-based antiretroviral therapy: a systematic review and meta-analysis","volume":"12","author":"Valenzuela","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jiph.2024.102630_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002385","article-title":"Plasma efavirenz concentrations are associated with lipid and glucose concentrations","volume":"95","author":"Sinxadi","year":"2016","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.jiph.2024.102630_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s43856-022-00170-z","article-title":"The demographic and socioeconomic correlates of behavior and HIV infection status across sub-Saharan Africa","volume":"2","author":"Patel","year":"2022","journal-title":"Commun Med"},{"key":"10.1016\/j.jiph.2024.102630_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12905-022-01814-x","article-title":"\u201cIt\u2019s only fatness, it doesn\u2019t kill\u201d: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda","volume":"22","author":"Alhassan","year":"2022","journal-title":"BMC Women'S Health"},{"key":"10.1016\/j.jiph.2024.102630_bib26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2024.102630_bib27","first-page":"e471","article-title":"Risk factors for weight gain following switch to integrase inhibitor\u2013based antiretroviral therapy","volume":"71","author":"Jordan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2024.102630_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2023.102807","article-title":"Weight gain in patients starting dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up","volume":"27","author":"Cardoso-Neto","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jiph.2024.102630_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12939-023-01952-0","article-title":"Socioeconomic inequalities in health outcomes among Thai older population in the era of universal health coverage: trends and decomposition analysis","volume":"22","author":"Kaikeaw","year":"2023","journal-title":"Int J Equity Health"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124003642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124003642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T04:57:28Z","timestamp":1740632248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034124003642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1876034124003642"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2024.102630","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2024.102630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102630"}}